Vertex Pharmaceuticals to Webcast its 2005 Annual Meeting of Shareholders Cambridge, MA, May 5, 2005 -- Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) will webcast its 2005 Annual Meeting of Shareholders on Wednesday, May 11, 2005. Joshua Boger, Ph.D., Vertex's Chairman and Chief Executive
First HCV protease inhibitor in pivotal trial for this difficult<br> to treat patient population<br><br> Trial to enroll all major treatment-failure patient groups,<br> including null responders, partial responders and relapsers<br><br> Two telaprevir registration programs to address significant unmet<br> need in treatment-naive and treatment-failure patients
CAMBRIDGE, Mass., Sep 30, 2009 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it will receive $155 million in cash from two financial transactions. In the first transaction, Vertex will receive approximately $120 million in cash for the issuance of notes
<i>-PROVE 3 results to be presented at late breaker session on Saturday,
April 25, 2009-</i><i>-Interim data from two Phase 2 studies of telaprevir indicate
activity across multiple genotypes in treatment-naïve HCV patients-</i><i>-Early data from newly-acquired polymerase inhibitors suggest rapid,
powerful antiviral activity with favorable safety and tolerability
profile-</i>
Vertex Pharmaceuticals to Focus 2006 Clinical Development on Therapies for Hepatitis C Virus Infection, Inflammation and Cystic Fibrosis Cambridge, MA, October 4, 2005 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that it will concentrate its development investment in 2006 on
-- Primary Phase 3 trial will focus on studying 24-week telaprevir-based regimens -- Vertex plans concurrent second study to support registration -- Final data from both trials anticipated in mid- 2010
<i>- Vertex to acquire privately-held ViroChem Pharma in cash and stock
transaction -</i><i>- Two HCV polymerase inhibitors, VCH-222 and VCH-759, have
demonstrated significant antiviral activity in early clinical trials -</i><i>- First STAT-C combination trial with telaprevir planned for 2H 2009
start -</i>
CAMBRIDGE, Mass., Jun 03, 2008 (BUSINESS WIRE) -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that it has sold its rights to future royalties in Lexiva(R) and Agenerase(R) under its 1993 license agreement with GlaxoSmithKline plc (GSK) in the field of HIV protease inhibitors
<i>- Telaprevir registration program on track; VCH-222 enters
multi-dose, 3-day viral kinetic study -</i><i>- VX-770 will start registration program in CF patients with G551D
mutation -</i><i>-Vertex ends first quarter with $869 million of cash, cash
equivalents and marketable securities-</i>
